



# İSTANBUL PROJECT ACADEMY



MARMARA ÜNİVERSİTESİ  
İNNOVASYON VE TEKNOLOJİ  
TRANSFER UYGULAMA VE  
ARAŞTIRMA MERKEZİ





Health Care  
Doctor  
Hospital  
Pharmacist  
Nurse  
Dentist  
First Aid  
Surgeon  
Emergency



MEDICAL



MEDICAL



MEDICAL

# Horizon Europe Cluster 1: Health Brokerage Event



**Project Idea / Field of Expertise :**

Orphan Drug Development for the Treatment of Terminal Pediatric Brain Cancer, DIPG

**Organisation Name:**

AGON Biyoteknoloji

**Addressed Topic(s) & Call(s):**

Call - Maintaining an innovative, sustainable and globally competitive health industry - HORIZON-CL1-2023-D6-01

Call - Tackling diseases and reducing disease burden- HORIZON-CL1-2024-D3-01-two stage



# Organisation name

- AGON Biotech was founded in 2021. AGON Biotechnology, which carries out research and development projects on biosensors and medical devices, has started to develop and produce electronic components as well as bacterial sensors by receiving various government grants.
- Biosensors, Genetic Research, Microbiology



PATENT

PATENT APPLICATION



ECOSYSTEM

- ENTREPRENEUR MENTORING
- FOREIGN AND INTERNATIONAL INVESTOR MEETINGS
- ACCELERATOR PROGRAMS
- GOVERNMENT FUNDS AND GRANTS



TEKNOPARK

DEPARK



ÖDÜLLER

+10'DAN FAZLA ÖDÜL




CORP.

TÜBİTAK 1512 - 2021

# Orphan Drug Development for the Treatment of Terminal Pediatric Brain Cancer, DIPG

## Problem:

Brain tumours are one of the most common cancers in childhood. Diffuse Intrinsic Pontine Glioma (DIPG), a pons tumour, is among these brain tumours. Most patients are diagnosed before the age of seven. The average survival time after diagnosis is 9 months.



## Solution:

Our project, it was aimed to prolong the patient's life expectancy and control symptoms by editing existing mutations of the specific gene for DIPG. This gene therapy the biggest reason for choosing the method is that viruses can cross the brain-blood barrier and the treatment can be delivered to the desired area. The vaccine to be obtained as a result of the project is known as an **orphan drug**.

## Target:

Our target audience consists of children with DIPG brain tumours. In the United States alone, 200 to 400 children are diagnosed with DIPG each year. In addition, upon the verification of the technology used and its benefits, similar gene therapy methods form the basis of the technology that can be used for different diseases.



# Contact details



Contact person	<b>Aleyna YILDIZ</b>
Organisation	AGON Biotechnology
Address	İnciraltı Mah. Mithatpasa Cad. Morphology Block: 56-20 P01 Balçova/İzmi
Phone	+90 534 591 32 84
E-mail	aleynayildiz@agonbiotechnology.com
B2Match profile	<a href="https://brokerage-event-focusing-on-cl1.b2match.io/my">https://brokerage-event-focusing-on-cl1.b2match.io/my</a>
LinkedIn/Twitter	<a href="https://www.linkedin.com/in/aleynayildizz/">https://www.linkedin.com/in/aleynayildizz/</a>



**ISTANBUL  
PROJECT  
ACADEMY**



**THANK YOU...**



MARMARA ÜNİVERSİTESİ  
İNNOVASYON VE TEKNOLOJİ  
TRANSFER UYGULAMA VE  
ARAŞTIRMA MERKEZİ

